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Analysis of chemokine receptor, and atypical chemokine receptor, expression is fre-
quently hampered by the lack of availability of high-quality antibodies and the species
specificity of those that are available. We have previously described methodology uti-
lizing Alexa-Fluor-labeled chemokine ligands as versatile reagents to detect receptor
expression. Previously this has been limited to hematopoietic cells and methodology for
assessing expression of receptors on stromal cells has been lacking. Among chemokine
receptors, the ones most frequently expressed on stromal cells belong to the atypical
chemokine receptor subfamily. These receptors do not signal in the classic sense in
response to ligand but scavenge their ligands and degrade them and thus sculpt in vivo
chemokine gradients. Here, we demonstrate the ability to use either intratracheal or
intravenous, Alexa-Fluor-labeled chemokine administration to detect stromal cell popu-
lations expressing the atypical chemokine receptor ACKR2. Using this methodology, we
demonstrate, for the first time, expression of ACKR2 on blood endothelial cells. This obser-
vation sets the lung aside from other tissues in which ACKR2 is exclusively expressed
on lymphatic endothelial cells and suggest unique roles for ACKR2 in the pulmonary
environment.
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 Additional supporting information may be found online in the Supporting Information sectionat the end of the article.
Introduction
In vivo leukocyte migration is regulated, in the main, by proteins
belonging to the chemokine family of chemotactic cytokines [1, 2].
This family is defined on the basis of a conserved cysteine motif in
the mature sequence of its members and is divided into CC, CXC,
XC, and CX3C subfamilies according to the specific configuration
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of this motif. The chemokine family arose early in vertebrate evo-
lution [3] (prevertebrate species do not have chemokines) and
the primordial chemokine was almost certainly CXCL12, which
plays essential roles in stem cell migration during embryogen-
esis [4-9]. From this one chemokine and its receptor CXCR4,
through gene duplication, the family has expanded to the point
at which mammals have approximately 45 chemokines, and 18
signaling chemokine receptors, which together orchestrate in vivo
homeostatic and inflammatory leukocyte migration. Chemokine
regulation of cellular migration is extremely complex and, partic-
ularly in the case of inflammation [10], poorly understood, which
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has contributed to ongoing problems in therapeutically targeting
inflammatory chemokine receptors in immune and inflammatory
diseases [11].
In addition to signaling chemokine receptors that belong to
the G-protein-coupled receptor family [12], chemokines also bind
to a subfamily of atypical chemokine receptors (ACKRs), which
are generally stromally expressed and which fine-tune in vivo
chemokine activity by scavenging chemokines and therefore reg-
ulating chemokine availability [13-15]. There are currently four
members of the ACKR family: ACKR1 (formerly known as DARC),
ACKR2 (formerly known as D6), ACKR3 (formerly known as
CXCR7), and ACKR4 (formerly known as CCX-CKR). With the
exception of ACKR1, these receptors exhibit spontaneous internal-
ization and recycling activity and scavenge chemokines from the
environment and target them for lysosomal degradation. ACKR3
carries out this role in some essential developmental contexts and
is strongly evolutionarily conserved [5, 6, 16, 17]. ACKR4 scav-
enges chemokines within the LN to generate intra-LN gradients
and facilitate DC migration from the subcapsular sinus into the
T-cell zone of the LN [18]. We have had a particular interest
in ACKR2, which is the prototypic member of the ACKR family
[19]. This receptor binds, internalizes, and degrades all inflam-
matory chemokines belonging to the CC-chemokine subfamily and
thus plays an essential role in the resolution of the inflammatory
response [20-24]. This has implications for tumorigenesis [25-28]
as well as for branching morphogenesis in a number of develop-
mental contexts [29, 30]. ACKR2 is predominantly expressed on
lymphatic endothelial cells [31, 32] and placental trophoblasts
[23, 33, 34] with expression also being detected on subsets of
splenic B cells [35]. The ACKRs are therefore central regulators of
chemokine activity in vivo.
One of the challenges in studying chemokine receptors, includ-
ing ACKRs, is access to high-quality antibodies. While antibodies
to some typical and atypical receptors are available, it has proven
extremely difficult to raise useful antibodies to others. For exam-
ple, there are no high-quality antibodies available for detection of
murine ACKR2. A further issue is that even for receptors for which
antibodies are available, these antibodies are invariably species
specific and it is therefore difficult to carry out analyses in either
nonmurine or nonhuman species. This is particularly important for
highly conserved receptors such as ACKR3. The availability of a
generic methodology to allow detection of ACKRs (and amenable
to detection of typical receptors), which would be usable in vivo
and applicable to numerous species, would therefore represent a
significant technological development.
Here, we describe a novel methodology for the detailed anal-
ysis of the phenotypes of ACKR2-expressing cells in lung stroma.
The technology is conceptually similar to that reported by Ameti
and colleagues [36] and uses ACKR2-dependent internalization
of a fluorescently tagged ligand to identify receptor expressing
cells and we demonstrate the utility of comparing intratracheal
and intravenous administration in defining, and discriminating
between, discrete receptor expressing stromal cell types. Using
this approach, we report, for the first time, robust expression of
ACKR2 by pulmonary blood endothelial cells. This has not been
reported in any other tissues and suggests unique roles for ACKR2
in lung function and pulmonary immunity.
Results
ACKR2 is stromally expressed in the lung
Data on ACKR2 expression profiles available through the Imm-
gen database (www.immgen.org) reveal that the lung is the tis-
sue with the highest expression (Supporting Information Fig. 1).
We have previously described the versatile use of fluorescently
labeled chemokines, instead of antibodies, to detect their cog-
nate receptors using flow cytometry as a read out [35, 37-39].
We used this approach with Alexa-647-labeled CCL22 (a high-
affinity ACKR2 ligand: Alexa-CCL22) uptake to detect ACKR2 in
lung digests. Importantly, CCL22 also binds to the chemokine
receptor CCR4 so to control for any contribution of this recep-
tor to cellular CCL22 binding, and to confirm specific binding to
ACKR2, we have included ACKR2−/− mice and tissues in all our
analyses. Comparing CCL22 binding in WT and ACKR2−/− tis-
sues and cells therefore allows us to specifically determine the
expression patterns of ACKR2. Importantly, there are no differ-
ences in circulating levels of CCL22 between WT and ACKR2−/−
mice, which might confound these analyses (Supporting Informa-
tion Fig. 2). Further reasons for selecting CCL22 for this analysis
include the fact that this ligand does not display the broad receptor
binding profiles of other ACKR2 ligands and expression of CCR4 is
more limited than the receptors that bind the other ACKR2 ligands
[14]. Flow cytometric analysis of CD45+ cells from Alexa-CCL22-
stained lung digests failed to detect any significant expression
on CD45+ leukocytes in either WT or ACKR2−/− lungs (Fig. 1a).
The exemplar flow cytometry plot shown in Fig. 1a(i) revealed
a low level of Alexa-CCL22 binding to CD45+ cells in ACKR2−/−
lung digests, which is not seen in WT digests. We did not see
this routinely and repeated flow cytometric analyses (Fig. 1a(ii))
revealed essentially undetectable Alexa-CCL2 binding by either
WT or ACKR2−/− CD45+ cells. These data, therefore, indicated
that ACKR2 expression in the lung was predominantly stromal in
origin. We used RNA sequencing to generate data on the tran-
scriptional profile of FACS-sorted pulmonary stromal cell types
at rest and over the course of an influenza infection to exam-
ine possible pathogen-driven alterations in expression. As shown
in Fig. 1(b), ACKR2 expression was essentially undetectable in
epithelial cells but was present at low levels in fibroblasts and
at very high levels in blood endothelial cells. Expression did not
vary significantly over the course of influenza infection. Exam-
ination of pulmonary ACKR2 expression by qPCR from embry-
onic day 13.5 to 9 weeks of age indicated that expression is low
within the embryo but that it is markedly upregulated immediately
after birth and presumably coincident with the onset of breath-
ing. This increased level is maintained and increased as mice age
(Fig. 1c).
Next, we tried to use the in vitro Alexa-CCL22 detectionmethod
to examine ACKR2 expression on nonleukocytic stromal cells
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Figure 1. In vitro analysis of pulmonary ACKR2 expression. (a) (i) Flow cytometric analysis showing lack of expression of ACKR2 by CD45+ve
cells in lung digests as assessed by comparing Alexa-CCL22 uptake (X-axis) in WT and ACKR2−/− (KO) lungs. The Y-axis shows side scatter (SSC)
(n = 3 WT and 3 KO mice per experiment. The experiment was performed three times). (ii) Graph showing combined results of (i) for multiple
analyses of Alexa-CCL22 binding by CD45+ cells from the lung. There are no significant differences in the binding profiles of WT and ACKR2−/−
(KO) CD45+ cells. Error bars represent mean± SD. (b) Analysis of transcriptomic data generated from lung stromal populations showing low level
ACKR2 expression in fibroblasts but high-level expression in blood endothelial cells (analyzed using a bespoke bioinformatics pipeline available
through Glasgow Polyomics:www.polyomics.gla.ac.uk). These data were generated from resting lung stromal populations as well as from the same
populations retrieved from lungs at the indicated times (10 and 40 days) postinfluenza virus infection. (Data were generated and combined using
RNA from four separate lung cell harvests and the transctiptomic analyses performed once on these samples. Error bars represent mean ± SD.
(c) qPCR analysis of pulmonary ACKR2 expression from embryonic day E13.5 to adult 9-week-old mice. Data were normalized to expression of
the housekeeping gene Tata-binding protein. Statistical significance was tested using a one-way ANOVA test and ***p < 0.001. (Each time point
represents PCR data combined from four separate lung preps. PCR was performed on one occasion once all samples were obtained.) Error bars
represent mean ± SD. (d) Flow cytometric analysis of CD45-ve Alexa-CCL22 internalizing cells fromWT and ACKR2−/− lungs. The X-axis shows the
Alexa-CXCL22 binding, while the Y-axis shows staining for the epithelial marker EpCAM. (n = 3WT and 3 KOmice per experiment. The experiment
was performed three times.) (e) Quantification of the percentage of ACKR2+ve stromal cells detected using this Alexa-CCL22 in vitro labeling
approach. Data are combined from three experiments with n = 3 mice/group. Statistical significance was tested using Student’s T test and *p <
0.05. Error bars represent mean ± SD.
in the digested lung. However, and as shown in Fig. 1d, this
technology, which works well with leukocytes [35, 39, 40] and
mammary gland fibroblasts [30], revealed only a minor differ-
ence in the numbers of Alexa-CCL22 internalizing cells in WT
or ACKR2−/− lungs. These data are summarized numerically in
Fig. 1e.
Overall, therefore, these data indicate that ACKR2 is predom-
inantly expressed on stromal cells within the lung but that flow
cytometry utilizing fluorescent chemokine uptake with digested
lung tissue has limited sensitivity to detect the key stromal express-
ing cell types. Importantly, the Alexa-CCL22 was added to the
lung cells after digestion was completed and the cells washed.
There is therefore unlikely to be any contribution of proteolytic
degradation of the ligand to the weak binding results obtained in
these experiments.
Intratracheal fluorescent chemokine administration
detects key ACKR2-expressing stromal components
We reasoned that the function of stromal ACKR2 expression may
be dependent on interactions with other stromal components and
that the inability to detect it using flow cytometry reflects the
inability to take up Alexa-CCL22 due to absence of these interac-
tions. We therefore harvested intact lungs and inflated them with
Alexa-CCL22 (in RPMI) intratracheally followed by incubation at
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Figure 2. Detection of stromal ACKR2 expression by intratracheal administration of Alexa-CCL22. (a) Diagram indicating the basic methodology
that involves removing intact lungs and inflating them through the trachea using an RPMI/Alexa-CCL22mix. The lung is then incubated at 37°C for
1 h, then digested and prepared for flow cytometry. (b) Flow cytometric analysis showing the presence of a significant Alexa-CCL22 internalizing
stromal component in the lung. The X-axis shows the Alexa-CXCL22 binding/internalization, while the Y-axis shows staining for the epithelial
marker EpCAM. (n = 3 WT and 3 KO mice per experiment. The experiment was performed three times.) (c) Quantification of the levels of stromal
ACKR2 detected in WT and ACKR2−/− (KO) lungs following intratracheal Alexa-CCL22 administration. Data are combined from three experiments
with n = 3 mice/group. Statistical significance was tested using Student’s T test and *p < 0.05. Error bars represent mean + SD. (d) Flow cytometric
analysis of the CD45-ve EpCAM-ve nonepithelial stromal component expressing ACKR2 on the basis of CD31 and Gp38 expression. Data shown
are from Alexa-CCL22 binding lung stromal cells from WT (left plot) and ACKR2−/− (KO; right plot) mice. (n = 3 WT and 3 KO mice per experiment.
The experiment was performed three times.) (e) Summary analysis of the percentage of CD45-ve stroma associated with each of the indicated
cell types following intratracheal administration of Alexa-CCL22. Data are combined from three experiments with n = 3 mice/group. Error bars
represent mean ± SD.
37°C for 1 h (Fig. 2a). Following this, flow cytometric analysis
of digested lungs focusing on CD45-ve cellular populations now
revealed a sizeable population of Alexa-CCL22 internalizing cells
in WT lungs, which are absent from ACKR2−/− lungs (Fig. 2b).
These cells are nonepithelial as they are negative for EpCAM
staining and these data are summarized numerically in Fig. 2c.
Further flow cytometric analysis indicated that these cells fall into
three basic categories as defined by CD31 and Gp38 expression
(Fig. 2d). These represent fibroblasts (R1; CD31−Gp38−), lym-
phatic endothelial cells (R2; CD31+Gp38+), and blood endothe-
lial cells (R3; CD31+Gp38−), which are enumerated as shown in
Fig. 2e.
Overall, these data demonstrate that it is possible to detect
stromal cell populations that bind and internalize Alexa-CCL22
via ACKR2 by introducing the chemokine intratracheally into the
intact lung. They also demonstrate novel stromal expression pat-
terns for ACKR2 within the lung.
A subpopulation of fibroblasts in the lung expresses
ACKR2
Cells identified in the R1 gate in Fig. 2d, which were negative for
markers of lymphatic and vascular endothelial cells, were further
phenotyped. Initially, these cells were isolated by cell sorting and
then grown in tissue culture. As shown in Fig. 3a, the cells display
a morphology suggestive of a fibroblastic phenotype. Flow cyto-
metric analysis revealed that these cells are negative for markers
of epithelial (CD166) and endothelial (CD49f) cells but positive
for the fibroblastic marker CD140a (Fig. 3b). The CD140a+ve
cells can be subdivided into three populations based on Sca-1
staining and SSC. Further Alexa-CCL22 binding assays revealed
that the dominant ACKR2-expressing population was Sca-1 high
and SSC lo/mid in phenotype (Fig. 3c). Figure 3d further shows
that sorted ACKR2+ fibroblastic cells were capable of binding
Alexa-CCL22 as indicated by the extensive fluorescence (arrows),
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Figure 3. Identification of a fibroblastic population as a component of the ACKR2-expressing stromal population. (a) Brightfield image of cells
sorted for internalization of fluorescently labeled Alexa-CCL22. These cells are negative for Gp38, CD45, andCD31 expression (n= 3). (Representative
image from three separate in vitro cultures.) Image captured at 63× magnification. Scale bar: 10 µm. (b) Flow cytometric analysis of the fibroblastic
population showing absence of expression of epithelial (CD166) and endothelial (CD49f) markers but positive expression of fibroblastic markers
(CD140a). (n = 3 mice per experiment. The experiment was performed three times.) (c) (i) Flow cytometry profile showing Sca-1 staining and SSC
for the CD140a+ fibroblast population. (ii) Flow cytometric analysis of Alexa-CCL22 binding by each of the 3 Sca-1+ve populations. (n = 3 WT and 3
KO mice per experiment. The experiment was performed three times.) (d) Fluorescent confocal image of ACKR2+ve fibroblastic cells binding and
internalizing Alexa-CCL22 (arrowed). (Representative image from three separate in vitro cultures). Image captured at 63× magnification. Scale bar:
10 µm.
confirming expression of functional ACKR2 (Fig. 3b). Given the
punctate nature of much of this staining, we propose that it is
largely intracellular in nature. Overall these data indicate that one
of the ACKR2-expressing stromal components in the lung detected
by intratracheal Alexa-CCL22 administration is a fibroblastic sub-
population characterized by CD140a and Sca-1 expression.
Intravenous fluorescent chemokine administration
detects further ACKR2-expressing stromal components
We have previously reported expression of ACKR2 in lymphatic
endothelial cells [31], however expression in blood endothelial
cells as shown in Fig. 2d and e has not been reported. In fact,
and as shown in Supporting Information Fig. 3, comparison of
transcriptomic data from a broad range of microvascular endothe-
lial types indicates that expression in blood endothelial cells is
peculiar to the lung. Given that we have reported polarization of
expression of ACKR2 in trophoblasts and lymphatic endothelial
cells [31, 34, 41], we wondered whether it may also be polarized
in blood endothelial cells. If this is the case, then it is possible that
the vascular facing aspect of endothelial cells may be more able to
internalize Alexa-CCL22 and thus the blood endothelial cell com-
ponent might be underestimated by the intratracheal administra-
tion of the chemokine. We therefore next injected Alexa-CCL22
intravenously (Fig. 4a) and then harvested the lung for flow
cytometric analysis of Alexa-CCL22 cellular interactions. Again,
this analysis revealed that Alexa-CCL22 was not bound by lung-
resident CD45+ cells (data not shown) but uptake was seen in
three populations of nonepithelial stromal cells in WT but not
ACKR2−/− lungs. These populations comprised fibroblasts, blood
endothelial cells, and lymphatic endothelial cells (Fig. 4b). How-
ever, and in contrast to intratracheal administration, intravenous
administration detected blood endothelial cells as being by far
the dominant ACKR2-expressing stromal population. Figure 4c
shows that intravenous administration highlights blood endothe-
lial cells as being the predominant stromal cell component in the
lung and comparing intratracheal administration with intravenous
C© 2020 The Authors. European Journal of Immunology published by
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Figure 4. Intravenous administration of Alexa-CCL22 reveals strong expression of ACKR2 on the luminal face of pulmonary vascular endothelial
cells. (a) Diagram indicating intravenous injection of Alexa-CCL22 into live mice. (b) Flow cytometric analysis of CD31 (X-axis) and Gp38 (Y-axis)
expression by CD45-ve EpCAM-ve stromal cells that internalize Alexa-CCL22 in ACKR2−/− (KO) and WT lungs. The identified populations are
indicated. (n = 3 WT and 3 KO mice per experiment. The experiment was performed three times.) (c) Quantification of the % of CD45-ve stromal
cellular populations internalizing Alexa-CCL22 following intravenous administration of Alexa-CCL22. Data are combined from three experiments
with n = 3 mice/group. Error bars represent mean ± SD. (d) Comparison of intratracheal and intravenous administration and the impact on the
relative size of the ACKR2+ stromal cell populations detected by flow cytometry. Fib., fibroblasts; LEC, lymphatic endothelial cells; BEC, blood
endothelial cells. Data are combined from three experiments with n = 5 mice/group. Error bars represent mean ± SD. (e) Flow cytometric analysis
of the CD31+ve, Alexa-CCL22 internalizing blood endothelial cells indicate that they are positive for expression of CD54 and negative for CD106
and thus are alveolar, rather than peribronchial, endothelial cells. Red: the gated CD31+ cells that have been antibody stained; blue, fluorescence
minus one (FMO) control. (n = 5 mice per experiment. The experiment was performed twice.)
administration (Fig. 4d) reveals the differences in cellular detec-
tion using these two approaches. As we have previously shown
expression of ACKR2 by lymphatic endothelial cells [31, 32], it
remained possible that what we have characterized as lung blood
endothelial cells are in fact lung lymphatic endothelial cells dis-
playing an altered CD31/Gp38 phenotype compared to other lym-
phatic endothelial cell populations. To formally test this, we exam-
ined lung lymphatic endothelial cell expression of CD31 and Gp38
using Prox-1 reporter mice. Prox-1 is a definitive marker and an
essential master regulator of lymphatic endothelial cells [42]. As
shown in Supporting Information Fig. 4, Prox-1+ve cells from
reporter mouse lungs were exclusively co-positive for CD31 and
Gp38, confirming the faithfulness of the lymphatic phenotype in
the lung. These data further confirm the blood endothelial nature
of the ACKR2+ve stromal cells.
In the lung, there are two major blood vascular beds: one asso-
ciated with bronchial tissues and one with alveolar tissues. These
can be discriminated on the basis of CD54 and CD31 expression
[43]. As shown in Fig. 4e, the Alexa-CCL22 internalizing blood
endothelial cell population is strongly co-positive for CD31 and
CD54, demonstrating that this population is associated with alve-
olar blood vessels and not peribronchial blood vessels.
In situ hybridization and antibody expression confirm
blood endothelial cell expression of ACKR2
To further validate ACKR2 expression bymurine pulmonary vascu-
lar endothelial cells, we carried out in situ hybridization. As shown
in Fig. 5a, clear in situ hybridization signals were seen associated
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Figure 5. In situ and antibody detec-
tion of ACKR2 on pulmonary alveolar
blood endothelial cells in mouse and
human lung. (a) Representative in situ
hybridization showing positivity for
ACKR2 expression in alveolar endothe-
lial cells in murine lungs (arrow). (i)
WT lungs and (ii) ACKR2−/− lungs.
Note the absence of signal in alveolar
macrophages. Image captured at 10×
magnification. Scale bars: 200 µm. (n
= 3 mice per experiment. The exper-
iment was performed twice). (b) High
power image cropped from (i) show-
ing the peri-alveolar localization of
the vascular staining. This image has
been amplified 2× and the scale bar =
100 µm.
with alveolar endothelial cells in blood vessels surrounding the
alveolar air space in WT, but not ACKR2−/−, adult murine lungs.
A higher magnification image of a portion of Fig. 5a(i) is shown
in Fig. 5b, further highlighting the peri-alveolar localization of the
vascular staining. Therefore, in situ hybridization confirms blood
endothelial cell expression of ACKR2 in the murine lung.
Discussion
ACKRs are predominantly expressed on stromal cell types and
serve key functions in localizing and fine-tuning chemokine activi-
ties [15]. While a number of antibodies and reporter mouse-based
approaches are available for analysis of ACKR expression patterns,
in many cases these are limited and applicable only to mouse and
humans. Given that many of the ACKRs display strong evolution-
ary conservation, other more versatile approaches would therefore
represent a significant improvement in the methodological reper-
toire for ACKR expression analysis. Here, we demonstrate, using
the lung, that fluorescently labeled chemokines can be used, with
intact tissues, to precisely isolate and phenotypically define stro-
mal cell types expressing individual ACKRs. This is particularly
important when, as in the current analyses, removal of the cells
from their stromal environment impairs ACKR2 function and thus
frustrates this detection methodology. The ability to chemically
synthesize chemokines with relative ease and to introduce discrete
fluorescent markers at the carboxy terminus [40] means that this
approach has full versatility and is appropriate for all members of
the chemokine receptor family and all species expressing either
typical or ACKRs. Importantly, while we demonstrate the utility
of this approach using WT and KO mice, the use of appropriate
unlabeled competing chemokines specific for the receptor being
studied will allow this technology to be used under circumstances,
or in species, where KO models do not exist.
Here, we show that intratracheal, and intravenous, adminis-
tration of fluorescently labeled CCL22 is capable of identifying
stromal cell populations expressing ACKR2. Importantly, in the
context of vascular endothelial cell expression, intravenous admin-
istration has the advantage of detecting chemokine receptor
expression with a polarity favoring expression on the luminal
side of the endothelium. Together these approaches allowed us
to define fibroblasts, lymphatic endothelial cells, and surprisingly
alveolar blood endothelial cells as key sites of stromal ACKR2
expression in the lung. Notably, and in contrast to previous reports,
we did not detect ACKR2 activity on alveolar macrophages [44,
45]. This may be due to species differences in expression or alter-
natively may be a consequence of nonspecific antibody internal-
ization by the alveolar macrophages. Further analysis is required
to address this discrepancy.
In summary, therefore we report a methodology appropriate
for detecting ACKR expression in the lung, which we believe to be
sufficiently versatile to be useful to detect other atypical and typi-
cal chemokine receptors in numerous tissues in vivo in divergent
species. The data indicate for the first time the stromal expression
patterns of ACKR2 in the lung with notably high expression levels
on alveolar endothelial cells. These data will help interpret the
outcome of analysis of ACKR2 function in the lung, which remains
poorly defined.
Materials and Methods
Mice
Animal experiments were performed using cohoused mice in
ventilated cages in a barrier facility that conformed to the animal
care and welfare protocols approved by the University of Glasgow
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under the revised Animal (Scientific Procedures) Act 1986 and
the European Union Directive 2010/63/EU. Ackr2-deficient
mice21 were bred in-house (C57BL/6 background); wild-type
(WT) C57BL6/J mice were from Charles River Research Models
and Services. Prox-1 reporter mice were obtained from Jackson
laboratories. All experimental mice were sex and age matched.
qPCR
RNA was extracted using RNeasy columns with DNase treat-
ment (Qiagen), and the amount of RNA was quantified on a
Nanodrop 1000 Spectrophotometer (Thermo Fisher Scientific).
cDNA was synthesized using High-capacity RNA-to-cDNA kit
by Applied Biosystems (Thermofisher). For all qPCRs, a final
concentration of 0.2 mM primers was used for each PCR set
up using PerfeCTa SYBR Green FastMix and ROX qPCR Master
Mix (Quanta BioSciences). qPCRs were performed on a Prism
7900HT Fast Real-Time PCR System (Applied Biosystems). The
thermal cycles for qPCR of TBP and ACKR2 were 95˚C (3 min)
for one cycle and 95˚C (3 s) and 60˚C (30 s) for 40 cycles.
Relative expression was calculated using serial dilutions of
cDNA standards. Primer sequences designed for qPCR and for
producing cDNA standards were designed using Primer3 software
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi).
The following primers were used: mouse ACKR2, 5′-
TTCTCCCACTGCTGCTTCAC-3′, 5′-TGCCATCTCAACATCACAGA-
3′; mouse TBP primer: 5′- AAGGGAGAATCATGGACCAG-3′, 5′-
CCGTAAGGCATCATTGGACT-3′.
In situ hybridization
Mice were culled using increasing concentration of CO2. Lungs
were placed in 10% neutral buffered formalin at room tempera-
ture for 24–36 h before they were processed by dehydration using
rising concentrations of ethanol, xylene stabilization, and paraf-
fin embedding (Shandon citadel 1000; Thermo Shandon). Tissue
was then sectioned onto Superfrost plus slides (VWR) at 6 µm
using a Microtome (Shandon Finesse 325 Microtome; Thermo).
All slides for analysis were processed together. Slides were baked
at 60°C for 1 h before pretreatment. Slides were deparaffinized
with xylene (5 min × 2) and dehydrated with ethanol (1 min
× 2). In situ hybridization was performed using the RNAscope R©
2.5 HD Reagent Kit-RED from Advanced Cell Diagnostics (cat.
no. 322350) and according to the manufacturer’s instructions.
Briefly, tissues were incubated with hydrogen peroxide for 10 min
at RT. The slides were boiled in antigen retrieval buffer for 15 min.
Slides were treated with “protease plus” for 30 min at 40°C. Slides
were then hybridized using the RNAScope 2.5 Red Manual Assay
(Advanced cell diagnostics) according to manufacturer’s instruc-
tions using the Mm-ACKR2 probe (NM 021609.4). Slides were
mounted in DPX (Sigma Aldrich) and imaged on an EVOS M7000
microscope (Thermofisher).
Intratracheal and intravenous chemokine
administration
To administer fluorescent chemokine intratracheally, mice were
euthanized using an appropriate schedule 1 method or CO2 expo-
sure. The mice were then carefully dissected to remove the ribcage
and expose the intact lungs and trachea in situ. Using a pair
of surgical scissors, a small incision was made at the top of the
exposed trachea toward the base of the jaw. A 2 µg/mL solution
of Alexa 647TM labeled CCL22 (Almac; Alexa-CCL22) dissolved in
RPMI/25mM HEPES was prepared in a polypropolene tube and
preserved from light at room temperature until needed. Once the
dissection was complete, a syringe with a 19G needle and loaded
with 400 µL of the Alexa-CCL22 solution was then inserted into the
exposed trachea via the incision. The needle should be tight within
the trachea and care should be taken not to pierce the trachea
further down. The lungs were then inflated with the chemokine
solution and the trachea carefully tied off with surgical thread
to prevent the leakage of chemokine solution as the syringe is
removed. The intact inflated lungs were then removed and placed
into a falcon tube containing enough RPMI to cover the intact
inflated lungs. The lungs were then incubated in a water bath for
1 h at 37°C. Following this time, the lungs were removed from
the water bath and the surgical thread cut to allow draining of the
remaining chemokine solution. The lungs were then digested for
a single cell suspension as per the protocol.
Flow cytometry
All flow cytometry analyses adhered to published guidelines for
use of flow cytometry and cell sorting in immunological studies
[46]. Lungs were removed and finely chopped with scissors,
then incubated in digestion mix (1.6 mg/mL Dispase [Roche],
0.2 mg/mL Collagenase P [Roche], and 0.1 mg/mL DNase I
[Invitrogen]) in HBSS on a gentle shake at 37°C for 40 min. Lungs
were passed through a 40 µmmesh (Greiner Bio-One), RBCs were
lysed in 1 mL RBC lysis buffer (eBioscience) for 1 min, and then
in 10 mL FACs buffer (PBS, 1% FCS, 0.02% sodium azide, 5 mM
EDTA) to quench the reaction. The resulting single cell suspension
was preincubated with Fc block (BD Biosciences) in FACS buffer
(PBS, 1% FCS, and 5 mM EDTA) and labeled with fluorescent
anti-mouse Abs, including CD45 (30-F11), Gp38 (8.1.1), CD140a
(APA5), EpCAM-1 (G8.8), CD31 (390), and CD49f (GoH3),
each labeled with various fluorochromes (Biolegend) CD166
(eBioALC48) (Ebioscience). Dead cells were labeled using Fixable
viability dye efluor 506 or efluor 780 (ebioscience). Cells were
stained for 20 min on ice before washing with FACS buffer. Cells
were either analyzed by flow cytometry immediately or fixed for
20 min with 2% methanol-free paraformaldehyde (Invitrogen)
before washing and placing at 4°C in the dark until ready to be
analyzed typically 12–24 h later. Cells were analyzed using LSR2
flow cytometers (Beckton Dickinson) or sorted on a FACSAria.
Data were analyzed using FlowJo Version 9.2 software (TreeStar)
with populations defined by size, viability, and “fluorescence
C© 2020 The Authors. European Journal of Immunology published by
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minus one” isotype controls. Gating strategies are shown in
Supporting Information Fig. 5.
Immunofluorescence
Alexa-CCL22 labeled ACKR2+ fibroblasts were flow-sorted from a
single cell suspension using the ARIAII (Beckman and Dickinson)
as per the flow protocol. ACKR2+ fibroblasts were resuspended
in PBS at a density of 2000 cells/mL. Note that 100 µL of this
cell suspension was loaded into a cytospin 3 machine (Thermo-
Shandon) and the cells were spun for 5 min at 200 rpm onto
SuperfrostTM plus slides. The cells were air dried in the dark and
mounted in Vectashield Hard set mounting medium (Vector Lab-
oratories). The cells were visualized using a Zeiss Spinning Disc
confocal microscope.
Fibroblast culture and analyses
Primary ACKR2 positive fibroblasts were flow-sorted from a sin-
gle cell suspension using the ARIAII (Beckman and Dickinson) as
per the flow protocol. Retrieved cells were spun down at 400g for
5 min and washed three times into EMEMwith 15% FBS, 1× peni-
cillin/streptomycin, nonessential amino acids, and sodium pyru-
vate. The cells were plated at a density of approximately 5 × 103
cells per well of a 24-well plate (Gibco). Fibroblasts were cultured
as standard in an incubator at 37°C, 5% CO2.
Statistics
Statistical tests were carried out using Graph Pad Prism software
and the individual tests used are indicated in the relevant figure
legends. P = 0.05 was taken as a cut-off for statistical significance.
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